Masimo (MASI) W1 Watch With Hi to Improve Patient Outcome

Also Available, in Limited Market Release, Is Masimo W1 with Hydration Index, Designed to Provide Insight Into an Individual’due south Hydration

IRVINE, Calif.–(BUSINESS WIRE)– Masimo (NASDAQ: MASI) today announced the full market release of the Masimo W1™ health watch for consumer use. The offset of its kind, the Masimo W1 offers authentic, continuous measurements and insightful health data – from the leader in hospital pulse oximetry – in a personal, lifestyle-friendly, wrist-worn wearable. Building on Masimo’s decades of leadership in creating revolutionary noninvasive blood parameter monitoring solutions, Masimo W1 provides for the get-go fourth dimension in a watch format, accurate, continuous monitoring of oxygen saturation (SpO2), likewise every bit pulse rate, respiration charge per unit, and more, and, in a express market release, hydration index – for consumers wanting to ameliorate sympathize their overall wellness, amend their fettle, or share their wellness data with friends and family. Taking 86,400 measurements a day for 2d-past-second trending, the Masimo W1 watch represents the future of personal health.

This press release features multimedia. View the full release here: https://world wide web.businesswire.com/news/home/20220831005074/en/

Masimo W1™ (Graphic: Business organisation Wire)

Known for its exceptional accuracy and reliability during challenging atmospheric condition, such as motion and depression perfusion, Masimo is bringing its expertise in betoken processing, photonics, and bio-sensing to consumers looking to have control of their personal wellness, make better health decisions, and monitor their overall physiological status. Paired via secure Bluetooth®
to the Masimo Wellness™ smartphone app, Masimo W1 provides continuous health data, unlocking meaningful, actionable insights, with accuracy unheard of in a wearable or watch.

Launching aslope the Masimo W1 is Personal SafetyNet™, a paid subscription service integrated within the Masimo Health app that gives users access to sophisticated reporting tools to assist them review their physiological status over fourth dimension. In addition, Personal SafetyNet facilitates sharing data with family unit members, fettle trainers, health coaches, and where immune, healthcare providers, and even allows users the ability to set up virtual visits with doctors.

The Masimo W1 for consumers volition be available for directly-to-consumer purchase starting immediately at world wide web.masimo.com/masimo-w1. Masimo W1 comes with the Personal SafetyNet subscription service for consumers. Too arterial oxygen saturation and pulse rate, Masimo W1 can besides measure respiration rate, pleth variability index (PVi®), perfusion index, pulse rate variability (PRV), heart rate variability (HRV), steps, and, under limited market release terms, Hydration Index (How-do-you-do™). As part of a future update, Masimo W1 will besides be able to measure temperature and VO2Max and provide 24/vii health information tracking and oversight.

Hydration level has been one of the virtually sought out parameters past athletes, vocalists, and others seeking to optimize their performance. Since creating PVi – which allows clinicians to assess fluid responsiveness of mechanically ventilated patients – well-nigh xv years agone, Masimo has been working to invent a way to bring that measurement to consumers and those not on ventilators. Proper hydration is widely recognized equally an of import aspect of health and functioning, and lack of proper hydration affects many physiological parameters, as the body works to restore homeostasis. Masimo W1 establishes your hydration baseline, helping yous understand your hydration level, which non simply affects athletic performance and fatigue, just can behave significant risks, particularly for users with conditions similar congestive heart failure. Whether you’re an elite athlete, a vocalizer, living with a chronic affliction, or merely keen to gain more insight into your body’s physiological status, Masimo W1 with Hydration Index represents a breakthrough solution to better understanding and direction of hydration.

Olympic silvery medalist Morgan Pearson commented, “Masimo W1 is a gamechanger. As a professional triathlete, I’m always looking to optimize my functioning in every way possible. With Masimo W1 I can continuously monitor lots of vital signs, even my level of hydration. This essential continuous data volition help me runway and amend my physiological performance in the virtually demanding of race conditions.”

Dotsie Bausch, also an Olympic silver medalist, added, “Masimo W1 delivers the next generation of accuracy in wearables. I trusted Masimo technology to catapult me onto the Olympic podium as the oldest competitor in history in my field of study. Masimo delivers superior accuracy through movement, which is the gilt edge whatever athlete is looking for to produce their very best, every single time.”

Masimo is likewise entering the general launch phase of a medical version of Masimo W1 for use in medical applications outside the U.South., with additional measurement capabilities such every bit spot-bank check electrocardiogram (ECG), atrial fibrillation (A-fib) detection, and more. Benefiting from Masimo’due south expertise in hospital connectivity and hospital automation, the medical Masimo W1 will also be bachelor for employ in telehealth and telemonitoring applications via Masimo SafetyNet®
and Personal SafetyNet for healthcare providers and payers, every bit well every bit individual use. For patients taking opioids to reduce pain or recovering at abode after surgery or illness, as well as patients with chronic conditions (such as centre failure, COPD, or cancer), Masimo W1 will stand for a convenient, reliable remote monitoring and telehealth solution enabling hospitals and clinicians to proactively go on track of their patients’ physiological condition from distant, even as patients go nearly everyday tasks at home. A natural complement to the Masimo SafetyNet remote patient monitoring platform, Masimo W1 enables wireless transmission of patient data to the Masimo SafetyNet app and Masimo’s secure information deject, where information technology will be reviewed in near-real time by remote monitoring teams in centralized locations for signs of physiological reject or sudden changes, such as falls or spikes in heart rate.

In Kingdom of saudi arabia, where Masimo W1 is already approved for use in medical applications, Dr. Bakhsh, Head of the Middle Part Unit at Prince Sultan Cardiac Center, said, “Nosotros have begun using Masimo W1 with Masimo SafetyNet for remote patient monitoring of our chronic center failure patients. The scout is very comfortable to wear, and the continuous Masimo measurements give us confidence to help continue our patients condom.”

Dr. Chaudhry, Chief Clinical Data Officeholder (CCIO) and Main Data Officeholder (CIO) at Cambridge University Hospitals NHS Foundation Trust (CUH), said, “Nosotros take deployed Masimo Patient SafetyNet™ on our Intermediate Dependency Care Unit for continuous monitoring with pulse oximetry, and believe it has made a genuinely positive touch on the rubber of our patients. My initial feel with Masimo W1, the Masimo Wellness app and Personal SafetyNet monitoring service has been very positive. Equally we go forward caring for patients, whether in the infirmary or at home as part of the virtual wards we are setting upward, I am sure that this technology will be an excellent addition, supporting us in the delivery of ever increasing high-quality remote care for patients underpinned by personal, timely, and accurate clinical information.”

Dr. Amin, Professor of Medicine and Endowed Chair of Medicine at the University of California, Irvine, noted, “Masimo continues to innovate elegant noninvasive solutions to complex bug. The release of the Masimo W1 sentry raises the bar on home wearables by providing pulse oximetry based on industry-leading SET®
engineering science and continuous monitoring features in a wrist-worn device. By doing so, we can follow our health and fitness beyond the abode, to any location that has jail cell phone connectivity. I have personally worn Masimo W1 and am impressed by its comfort and stylish look—while able to continuously monitor my oxygen level, follow my step count, and rails other health parameters, both at rest and during activeness.”

Joe Kiani, Founder and CEO of Masimo, said, “With over thirty years of experience in medical monitoring and telemedicine, we are excited to bring the first wearable device to offer accurate and continuous pulse oximetry, hydration index, and other health measurements to consumers. The SET®
technology we invented for hospitals transformed patient monitoring, saved lives, and reduced the toll of care. Based on the feedback we take received from those who have tested Masimo W1 during the limited market release phase, we believe this watch volition ameliorate lives.”

In the U.S., Masimo W1 for utilise in medical applications is awaiting FDA clearance.

@Masimo | #Masimo

About Masimo

Masimo (NASDAQ: MASI) is a global medical technology company that develops and produces a broad array of industry-leading monitoring technologies, including innovative measurements, sensors, patient monitors, and automation and connectivity solutions. Our mission is to amend patient outcomes and reduce the cost of intendance. Masimo Gear up®
Measure-through Motion and Low Perfusion™ pulse oximetry, introduced in 1995, has been shown in over 100 contained and objective studies to outperform other pulse oximetry technologies.1
Masimo Set®
has also been shown to help clinicians reduce severe retinopathy of prematurity in neonates,2
improve CCHD screening in newborns,3
and, when used for continuous monitoring with Masimo Patient SafetyNet™ in post-surgical wards, reduce rapid response team activations, ICU transfers, and costs.4-7
Masimo Gear up®
is estimated to exist used on more than 250 million patients in leading hospitals and other healthcare settings around the globe,8
and is the chief pulse oximetry at 9 of the elevation 10 hospitals equally ranked in the 2022-23
U.Southward. News and World Report
All-time Hospitals Honor Gyre.9
Masimo continues to refine SET®
and in 2018, announced that SpOtwo
accuracy on RD Gear up®
sensors during weather condition of motion has been significantly improved, providing clinicians with even greater confidence that the SpO2
values they rely on accurately reflect a patient’due south physiological status. In 2005, Masimo introduced rainbow®
Pulse CO-Oximetry engineering, allowing noninvasive and continuous monitoring of blood constituents that previously could only be measured invasively, including total hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), Pleth Variability Index (PVi®), RPVi™ (rainbow®
PVi), and Oxygen Reserve Index (ORi™). In 2013, Masimo introduced the Root®
Patient Monitoring and Connectivity Platform, built from the basis up to be as flexible and expandable every bit possible to facilitate the addition of other Masimo and 3rd-party monitoring technologies; key Masimo additions include Next Generation SedLine®
Brain Part Monitoring, O3®
Regional Oximetry, and ISA™ Capnography with NomoLine®
sampling lines. Masimo’s family of continuous and spot-check monitoring Pulse CO-Oximeters®
includes devices designed for employ in a variety of clinical and non-clinical scenarios, including tetherless, vesture engineering, such equally Radius-7®
and Radius PPG™, portable devices like Rad-67®, fingertip pulse oximeters like MightySat®
Rx, and devices bachelor for use both in the hospital and at habitation, such as Rad-97®. Masimo hospital automation and connectivity solutions are centered around the Masimo Infirmary Automation™ platform, and include Iris®
Gateway, iSirona™, Patient SafetyNet, Replica®, Halo ION™, UniView®, UniView :60™, and Masimo SafetyNet®. In 2022, Masimo acquired Sound United, a leading developer of premium consumer sound and home integration technologies. Boosted information nigh Masimo and its products may be plant at world wide web.masimo.com. Published clinical studies on Masimo products can be found at www.masimo.com/prove/featured-studies/characteristic/.

ORi and RPVi have not received FDA 510(k) clearance and are not available for sale in the United States. The employ of the trademark Patient SafetyNet is under license from University HealthSystem Consortium.

References

  1. Published clinical studies on pulse oximetry and the benefits of Masimo SET®
    tin can be establish on our website at http://www.masimo.com. Comparative studies include contained and objective studies which are comprised of abstracts presented at scientific meetings and peer-reviewed journal manufactures.
  2. Castillo A et al. Prevention of Retinopathy of Prematurity in Preterm Infants through Changes in Clinical Practice and SpOii
    Applied science.
    Acta Paediatr.
    2011 February;100(2):188-92.
  3. de-Wahl Granelli A et al. Impact of pulse oximetry screening on the detection of duct dependent built center affliction: a Swedish prospective screening study in 39,821 newborns.
    BMJ.
    2009;Jan 8;338.
  4. Taenzer A et al. Bear upon of pulse oximetry surveillance on rescue events and intensive care unit transfers: a before-and-subsequently concurrence study.
    Anesthesiology. 2010:112(two):282-287.
  5. Taenzer A et al. Postoperative Monitoring – The Dartmouth Experience.
    Anesthesia Patient Safety Foundation Newsletter. Bound-Summer 2012.
  6. McGrath S et al. Surveillance Monitoring Management for Full general Care Units: Strategy, Design, and Implementation.
    The Joint Committee Journal on Quality and Patient Condom. 2016 Jul;42(7):293-302.
  7. McGrath Due south et al. Inpatient Respiratory Arrest Associated With Sedative and Analgesic Medications: Impact of Continuous Monitoring on Patient Bloodshed and Astringent Morbidity.
    J Patient Saf.
    2020 14 Mar. DOI: ten.1097/PTS.0000000000000696.
  8. Estimate: Masimo information on file.
  9. http://wellness.usnews.com/health-intendance/best-hospitals/articles/best-hospitals-honor-whorl-and-overview.

Forward-Looking Statements

This printing release includes forward-looking statements every bit divers in Department 27A of the Securities Act of 1933 and Department 21E of the Securities Substitution Act of 1934, in connexion with the Private Securities Litigation Reform Human activity of 1995. These forward-looking statements include, amidst others, statements regarding the potential effectiveness of Masimo W1. These frontward-looking statements are based on electric current expectations nigh future events affecting us and are subject field to risks and uncertainties, all of which are difficult to predict and many of which are across our control and could crusade our bodily results to differ materially and adversely from those expressed in our forward-looking statements as a result of various gamble factors, including, but non limited to: risks related to our assumptions regarding the repeatability of clinical results; risks related to our belief that Masimo’s unique technologies, including W1, contribute to positive clinical outcomes and patient safety; risks that Masimo W1 fails to be available as planned; risks related to our belief that Masimo noninvasive medical breakthroughs provide cost-effective solutions and unique advantages; risks related to COVID-19; likewise as other factors discussed in the “Risk Factors” department of our nearly recent reports filed with the Securities and Exchange Commission (“SEC”), which may exist obtained for free at the SEC’south website at www.sec.gov. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do non know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today’southward date. Nosotros do not undertake any obligation to update, amend or clarify these statements or the “Risk Factors” contained in our nearly contempo reports filed with the SEC, whether as a result of new information, hereafter events or otherwise, except as may be required under the applicable securities laws.


Masimo


Evan Lamb

949-396-3376

[electronic mail protected]

Irene Mulonni

Mulonni.com
858-859-7001

[email protected]

Source: Masimo

Source: https://investor.masimo.com/news/news-details/2022/Medical-Pioneer-Masimo-Announces-the-Full-Market-Consumer-Release-of-the-Masimo-W1-the-First-Watch-to-Offer-Accurate-Continuous-Health-Data/default.aspx

Check Also

Barclays downgrades Blackstone shares after firm limits withdrawals from real estate fund

Photograph Courtesy: Creative Commons/Twitter Real estate investment funds are similar to common funds in that …